Key result
The Clinical-GERAADA score demonstrated strong discriminative power for predicting 30-day mortality after TAAAD surgery (AUC 0.80; 95% CI 0.71-0.89), outperforming EuroSCORE II (AUC 0.77).
Why the study?
Reliable scores to predict mortality following surgery for type A acute aortic dissection are lacking, prompting evaluation of the newly developed GERAADA score compared with EuroSCORE II.
Does the Clinical-GERAADA score improve prediction of 30-day mortality compared to EuroSCORE II in patients undergoing type A acute aortic dissection surgery?
Observational (n=207)
No
Does the Clinical-GERAADA score improve prediction of 30-day mortality compared to EuroSCORE II in patients undergoing type A acute aortic dissection surgery?
The Clinical-GERAADA score, which incorporates both clinical and radiological evidence of malperfusion, provides strong discriminative power for predicting 30-day mortality after type A aortic dissection surgery, outperforming EuroSCORE II.
Answers are grounded in this paper and cite their sources.
Clinical-GERAADA may improve TAAAD operative risk prediction over EuroSCORE II; leaves open need for prospective validation before routine adoption.
OBJECTIVES: No reliable scores are available to predict mortality following surgery for type A acute aortic dissection (TAAAD). Recently, the German Registry of Acute Aortic Dissection Type A (GERAADA) score has been developed. We aim to compare how the GERAADA score performs in predicting operative mortality for TAAAD to the European System for Cardiac Operative Risk Evaluation (EuroSCORE) II. METHODS: We calculated the GERAADA score and EuroSCORE II in patients who underwent TAAAD repair at the Bristol Heart Institute. As there are no precise criteria to calculate the GERAADA score, we used 2 methods: a Clinical-GERAADA score, which evaluated malperfusion with clinical and radiological evidence, and a Radiological-GERAADA score, where malperfusion was assessed by computed tomography scan alone. RESULTS: 207 consecutive patients had surgery for TAAAD, and the observed 30-day mortality was 15%. The Clinical-GERAADA score showed the strongest discriminative power with an area under the curve (AUC) of 0.80 [95% confidence interval (CI) 0.71-0.89], while the Radiological-GERAADA score had an AUC of 0.77 (95% CI 0.67-0.87). EuroSCORE II showed acceptable discriminative power with an AUC of 0.77 (95% CI 0.67-0.87). CONCLUSIONS: Clinical GERAADA score performed better than the other scores and it is specific and easy to use in the context of a TAAAD. Further validation of the new criteria for malperfusion is needed.
No takes yet. Share an insight, caveat, or question.
Gemelli et al. (2023) conducted an observational in Type A acute aortic dissection (TAAAD) (n=207). Clinical-GERAADA score vs. EuroSCORE II and Radiological-GERAADA score was evaluated on 30-day mortality prediction (AUC) (AUC 0.80, 95% CI 0.71-0.89). The Clinical-GERAADA score demonstrated strong discriminative power for predicting 30-day mortality after TAAAD surgery (AUC 0.80; 95% CI 0.71-0.89), outperforming EuroSCORE II (AUC 0.77).
Synapse has enriched 10 related papers. Consider them for comparative context: